Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Completed Phase 1 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0029297 (Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00101270Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasTreatment